Content overview: “Australian advocates call for subsidised GLP-1 weight-loss drugs for women with PMOS”. Women living with Polyendrocrine Metabolic Ovarian Syndrome (PMOS) should have access to taxpayer-funded weight-loss medications, according to the Polyendrocrine Metabolic Ovarian Syndrome Association of Australia (POSAA). The advocacy group is urging for GLP-1 drugs to be approved on the Pharmaceutical Benefits Scheme (PBS) for people with the condition. Currently, GLP-1s are not specifically approved by the Therapeutic Goods Administration (TGA) to treat PMOS, so patients are being prescribed them off-label.
This means many women face high out-of-pocket costs, which can be a barrier to treatment. POSAA argues that subsidising these medications would improve health outcomes and reduce long-term complications associated with the syndrome. The call highlights the need for updated regulatory and funding decisions to reflect emerging evidence on GLP-1s for hormonal conditions. For the complete material, the listing points back to the source inside the network.